Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL365 Target Snapshot

Cryptococcus neoformans · ORGANISM · Cryptococcus neoformans

Back to Search Search this target Browse approvals Evidence Card
15,907Compounds
1,835Assays
6Approved Drugs
1,178.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cryptococcus neoformans as ChEMBL target CHEMBL365. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cryptococcus neoformans
ORGANISM · Cryptococcus neoformans
As of 2026-09-13
ChEMBL target ID
CHEMBL365
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cryptococcus neoformans still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCryptococcus neoformans
Target TypeORGANISM
OrganismCryptococcus neoformans
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCryptococcus neoformans
UniProt AccessionN/A

Cryptococcus neoformans

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Cryptococcus neoformans.

Review nameCryptococcus neoformans
OrganismCryptococcus neoformans
Clinical Profile

Clinical Phase Distribution

6
Approved
2
Phase III
Assay Mix

Activity Type Distribution

IC501,174.0
EC504.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL267345 9.7 IC50 0.2 Approved
CHEMBL106 8.3 IC50 5.0 Approved
CHEMBL157101 7.7 IC50 20.0 Approved
CHEMBL2441852 7.06 IC50 88.0 Preclinical
CHEMBL1630575 7.0 IC50 100.0 Approved
CHEMBL4226423 6.89 IC50 130.0 Preclinical
CHEMBL4226692 6.82 IC50 150.0 Preclinical
CHEMBL611024 6.8 IC50 160.0 Preclinical
CHEMBL3394576 6.75 IC50 180.0 Preclinical
CHEMBL4228173 6.7 IC50 200.0 Preclinical
Distribution

pChEMBL Value Distribution

29
5.0
39
5.5
69
6.0
22
6.5
5
7.0
1
7.5
1
8.0
0
8.5
0
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

CASPOFUNGIN
CHEMBL1630575
Approved 2001
Properties Compare Identifier
TERBINAFINE
CHEMBL822
Approved 1992
Properties Compare Identifier
FLUCONAZOLE
CHEMBL106
Approved 1990
Properties Compare Identifier
KETOCONAZOLE
CHEMBL157101
Approved 1981
Properties Compare Identifier
AMPHOTERICIN B
CHEMBL267345
Approved 1964
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,837
Total Assays
143
Tested Compounds
2
Assay Types
Functional — 1,836 assays, 143 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 1,780 143 5.7
assay format 56 0 —
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine